Last reviewed · How we verify
V7
V7 is an immunotherapeutic vaccine designed to stimulate the immune system against HIV infection.
V7 is an immunotherapeutic vaccine designed to stimulate the immune system against HIV infection. Used for HIV infection (therapeutic vaccine in treatment-experienced patients).
At a glance
| Generic name | V7 |
|---|---|
| Also known as | V7 or tableted heat-inactivated mycobacterium vaccae |
| Sponsor | Immunitor LLC |
| Drug class | Therapeutic vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
V7 is a therapeutic HIV vaccine candidate developed by Immunitor LLC that aims to boost cellular and humoral immune responses against HIV. The vaccine is intended to be used as an adjunctive therapy in HIV-infected patients to enhance immune control of the virus and potentially reduce viral load.
Approved indications
- HIV infection (therapeutic vaccine in treatment-experienced patients)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
- Biomarkers of Response to SEEG Thermocoagulation (NA)
- Blood Flow Conditions and Sounds in AVFs (NA)
- Biobank and Brain Health in Bordeaux.
- Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion (PHASE4)
- CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 (PHASE2)
- Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (PHASE2)
- Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V7 CI brief — competitive landscape report
- V7 updates RSS · CI watch RSS
- Immunitor LLC portfolio CI